Press release
B-cell Non-Hodgkin Lymphoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | AbbVie, Genmab, Novartis, AstraZeneca, Pacylex Pharma, Hutchison Medipharma, AbClon
DelveInsight's "B-cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the B-cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the B-cell Non-Hodgkin Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; B-cell Non-Hodgkin Lymphoma Market Forecast [https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the B-cell Non-Hodgkin Lymphoma Market Report:
*
The B-cell Non-Hodgkin Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
*
In December 2024, Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage biotechnology company developing advanced CAR T-cell therapies for solid tumors and hematologic malignancies, has announced promising initial clinical data from its multi-center Phase 1-2 study of IMPT-314 in patients with large B-cell lymphoma. The findings will be presented at the 66th American Society of Hematology (ASH) Annual Meeting. IMPT-314 is an autologous dual-targeting CD19/CD20 CAR T-cell therapy designed for treating aggressive B-cell non-Hodgkin lymphoma.
*
In November 2024, Enterome, a clinical-stage biotechnology company specializing in immunomodulatory cancer therapies through its proprietary Mimicry platform, has announced that clinical findings from the ongoing Phase 1/2 'SIDNEY' trial of EO2463, an investigational treatment for indolent non-Hodgkin B-cell lymphoma (iNHL), will be presented at the 66th American Society of Hematology (ASH) Annual Meeting.
*
According to the American Cancer Society, about 80,470 people (44,120 males and 36,350 females) will be diagnosed with NHL in the year 2022. This includes both adults and children
*
SEER, 2020, estimated that there would be near to 77,240 new cases of NHL in 2020 in the United States
*
B-cell lymphomas make up most (about 85%) of the NHL cases. Among the 7MM, our estimates shows that the highest Incident population of B cell-NHL was in the United States
*
SEER, 2020, estimated that there would be near to 77,240 new cases of NHL in 2020 in the United States
*
According to a study by Gena Kanas et al. (2021), the number of incident DLBCL cases in the US is projected from 29,108 to 32,443 and from 26,078 to 27,981 in WE (Western Europe) from 2020 to 2025, with a total rate of increase of 11% in the US compared to 7% in the WE
*
Key B-cell Non-Hodgkin Lymphoma Companies: AbbVie, Genmab, Novartis, AstraZeneca, Pacylex Pharma, Hutchison Medipharma, AbClon, Genmab, Hoffmann-La Roche, Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Regeneron Pharmaceuticals, ADC Therapeutics S.A., Jiangsu HengRui, Takeda, and others
*
Key B-cell Non-Hodgkin Lymphoma Therapies: Epcoritamab, Cyclophosphamide, GP2013, Capivasertib, PCLX-001, HMPL-760, AT101, rituximab, Mosunetuzumab, ME-401, Tazemetostat, Odronextamab, Loncastuximab Tesirine, SHR1459, TAK-007, and others
*
The B-cell Non-Hodgkin Lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage B-cell Non-Hodgkin Lymphoma pipeline products will significantly revolutionize the B-cell Non-Hodgkin Lymphoma market dynamics.
B-cell Non-Hodgkin Lymphoma Overview
NHL represents a heterogeneous group of malignancies of different biology and prognosis and can be divided into aggressive (fast-growing), intermediate, or indolent (slow-growing), and can develop from either B-cells or T-cells. Lymphomas that occur after allogeneic bone marrow or stem cell transplantation are usually B-cell non-Hodgkin lymphomas.
Get a Free sample for the B-cell Non-Hodgkin Lymphoma Market Report:
https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market [https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
B-cell Non-Hodgkin Lymphoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
B-cell Non-Hodgkin Lymphoma Epidemiology Segmentation:
The B-cell Non-Hodgkin Lymphoma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
*
Total Prevalence of B-cell Non-Hodgkin Lymphoma
*
Prevalent Cases of B-cell Non-Hodgkin Lymphoma by severity
*
Gender-specific Prevalence of B-cell Non-Hodgkin Lymphoma
*
Diagnosed Cases of Episodic and Chronic B-cell Non-Hodgkin Lymphoma
Download the report to understand which factors are driving B-cell Non-Hodgkin Lymphoma epidemiology trends @ B-cell Non-Hodgkin Lymphoma Epidemiology Forecast [https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
B-cell Non-Hodgkin Lymphoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the B-cell Non-Hodgkin Lymphoma market or expected to get launched during the study period. The analysis covers B-cell Non-Hodgkin Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the B-cell Non-Hodgkin Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
B-cell Non-Hodgkin Lymphoma Therapies and Key Companies
*
Epcoritamab: AbbVie
*
Cyclophosphamide: Genmab
*
GP2013: Novartis
*
Capivasertib: AstraZeneca
*
PCLX-001: Pacylex Pharma
*
HMPL-760: Hutchison Medipharma
*
AT101: AbClon
*
rituximab: Genmab
*
Mosunetuzumab: Hoffmann-La Roche
*
ME-401: Kyowa Kirin Co.
*
Tazemetostat: Eisai Co.
*
Odronextamab: Regeneron Pharma
*
Loncastuximab Tesirine
*
SHR1459: Jiangsu HengRui
*
TAK-007: Takeda
Discover more about therapies set to grab major B-cell Non-Hodgkin Lymphoma market share @ B-cell Non-Hodgkin Lymphoma Treatment Market [https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Scope of the B-cell Non-Hodgkin Lymphoma Market Report
*
Study Period: 2019-2032
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key B-cell Non-Hodgkin Lymphoma Companies: AbbVie, Genmab, Novartis, AstraZeneca, Pacylex Pharma, Hutchison Medipharma, AbClon, Genmab, Hoffmann-La Roche, Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Regeneron Pharmaceuticals, ADC Therapeutics S.A., Jiangsu HengRui, Takeda, and others
*
Key B-cell Non-Hodgkin Lymphoma Therapies: Epcoritamab, Cyclophosphamide, GP2013, Capivasertib, PCLX-001, HMPL-760, AT101, rituximab, Mosunetuzumab, ME-401, Tazemetostat, Odronextamab, Loncastuximab Tesirine, SHR1459, TAK-007, and others
*
B-cell Non-Hodgkin Lymphoma Therapeutic Assessment: B-cell Non-Hodgkin Lymphoma current marketed and B-cell Non-Hodgkin Lymphoma emerging therapies
*
B-cell Non-Hodgkin Lymphoma Market Dynamics: B-cell Non-Hodgkin Lymphoma market drivers and B-cell Non-Hodgkin Lymphoma market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
B-cell Non-Hodgkin Lymphoma Unmet Needs, KOL's views, Analyst's views, B-cell Non-Hodgkin Lymphoma Market Access and Reimbursement
To know more about B-cell Non-Hodgkin Lymphoma companies working in the treatment market, visit @ B-cell Non-Hodgkin Lymphoma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. B-cell Non-Hodgkin Lymphoma Market Report Introduction
2. Executive Summary for B-cell Non-Hodgkin Lymphoma
3. SWOT analysis of B-cell Non-Hodgkin Lymphoma
4. B-cell Non-Hodgkin Lymphoma Patient Share (%) Overview at a Glance
5. B-cell Non-Hodgkin Lymphoma Market Overview at a Glance
6. B-cell Non-Hodgkin Lymphoma Disease Background and Overview
7. B-cell Non-Hodgkin Lymphoma Epidemiology and Patient Population
8. Country-Specific Patient Population of B-cell Non-Hodgkin Lymphoma
9. B-cell Non-Hodgkin Lymphoma Current Treatment and Medical Practices
10. B-cell Non-Hodgkin Lymphoma Unmet Needs
11. B-cell Non-Hodgkin Lymphoma Emerging Therapies
12. B-cell Non-Hodgkin Lymphoma Market Outlook
13. Country-Wise B-cell Non-Hodgkin Lymphoma Market Analysis (2019-2032)
14. B-cell Non-Hodgkin Lymphoma Market Access and Reimbursement of Therapies
15. B-cell Non-Hodgkin Lymphoma Market Drivers
16. B-cell Non-Hodgkin Lymphoma Market Barriers
17. B-cell Non-Hodgkin Lymphoma Appendix
18. B-cell Non-Hodgkin Lymphoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bcell-nonhodgkin-lymphoma-market-to-show-remarkable-growth-trends-from-2023-to-2032-delveinsight-reports-abbvie-genmab-novartis-astrazeneca-pacylex-pharma-hutchison-medipharma-abclon]
Phone: +14699457679
Address:27 Drydock Ave S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release B-cell Non-Hodgkin Lymphoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | AbbVie, Genmab, Novartis, AstraZeneca, Pacylex Pharma, Hutchison Medipharma, AbClon here
News-ID: 3881385 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Lymphoma
Lymphoma Treatment Market - Liberating Lives from Lymphoma: State-of-the-Art Tre …
Newark, New Castle, USA: The "Lymphoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lymphoma Treatment Market: https://www.growthplusreports.com/report/lymphoma-treatment-market/8879
This latest report researches the industry structure, sales, revenue,…
Lymphoma Treatment Market - Inspiring Resilience, Shaping Survival: Innovations …
Newark, New Castle, USA - new report, titled Lymphoma Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Lymphoma Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Lymphoma Treatment market. The report offers an overview of the market, which…
Lymphoma Therapeutics Market: New Frontiers in Lymphoma Therapeutics | By AMR
Allied Market Research recently said Lymphoma is a type of cancer that affects the lymphatic system, which is an integral part of the body's immune system. While chemotherapy and radiation therapy have been the standard treatment options for lymphoma, recent advances in research have led to the development of new targeted therapies and immunotherapies.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/request-toc-and-sample/1448
One such targeted therapy is monoclonal antibodies, which can specifically target…
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;…
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company…
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of…
